Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Bevacizumab
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Abevmy 100mg/4ml concentrate for solution for infusion vials
0801050APBIAAAA
|
Abevmy | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Abevmy 400mg/16ml concentrate for inf vials
0801050APBIABAB
|
Abevmy | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Alymsys 100mg/4ml concentrate for inf vials
0801050APBEAAAA
|
Alymsys | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Alymsys 400mg/16ml concentrate for inf vials
0801050APBEABAB
|
Alymsys | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Avastin 100mg/4ml solution for infusion vials
0801050APBBAAAA
|
Avastin | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Avastin 400mg/16ml solution for infusion vials
0801050APBBABAB
|
Avastin | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Aybintio 100mg/4ml solution for infusion vials
0801050APBDAAAA
|
Aybintio | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Aybintio 400mg/16ml solution for infusion vials
0801050APBDABAB
|
Aybintio | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 1.25mg/0.05ml solution for injection vials
0801050APAAACAC
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 100mg/4ml solution for infusion vials
0801050APAAAAAA
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 400mg/16ml solution for infusion vials
0801050APAAABAB
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevqolva 100mg/4ml concentrate for inf vials
0801050APBJAAAA
|
Bevqolva | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevqolva 400mg/16ml concentrate for inf vials
0801050APBJABAB
|
Bevqolva | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Oyavas 100mg/4ml concentrate for solution for infusion vials
0801050APBFABAA
|
Oyavas | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Oyavas 400mg/16ml concentrate for inf vials
0801050APBFAAAB
|
Oyavas | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Vegzelma 100mg/4ml concentrate for inf vials
0801050APBGAAAA
|
Vegzelma | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Vegzelma 400mg/16ml concentrate for inf vials
0801050APBGABAB
|
Vegzelma | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Versavo 100mg/4ml concentrate for inf vials
0801050APBHAAAA
|
Versavo | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Versavo 400mg/16ml concentrate for inf vials
0801050APBHABAB
|
Versavo | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Zirabev 100mg/4ml solution for infusion vials
0801050APBCAAAA
|
Zirabev | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Zirabev 400mg/16ml solution for infusion vials
0801050APBCABAB
|
Zirabev | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.